Analyst Reports

  • 28 Sep 2023

    Edison Insight: September 2023

    Analyst: Pooya Hemami
    Actinogen Medical Investment Summary and Industry Outlook. Prices at 24 Apr 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 08 Jun 2023

    Edison Investment Research update
    Refining the upcoming XanaMIA Phase 2b study

    Analyst: Pooya Hemami

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 02 May 2023

    Edison Investment Research Quarterly update
    Continued focus on Xanamem

    Analysts: Pooya Hemami 

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 27 Apr 2023

    Edison Insight: April 2023

    Analyst: Pooya Hemami
    Actinogen Medical Investment Summary and Industry Outlook. Prices at 24 Apr 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 30 Mar 2023

    Edison Healthcare Insight: March 2023

    Analyst: Pooya Hemami
    Actinogen Medical Investment Summary and Industry Outlook. Prices at 27 Mar 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 15 Mar 2023

    Edison Investment Research H123 update
    Getting ready for the next Alzheimer’s study

    Analysts: Pooya Hemami 

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 09 Feb 2023

    Edison Healthcare Insight: February 2023

    Analyst: Pooya Hemami
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 6 Feb 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 12 Jan 2023

    Spark Plus Research Note
    Actinogen – A company to never forget

    Analyst: Cyprus Sia

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Spark Plus Pte Ltd. The report solely reflects the views of Spark Plus Pte Ltd.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Spark Plus Pte Ltd at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 06 Jan 2023

    Edison themes: Outlook for 2023
    Biotechs remain central to novel drug development

    Analyst: Soo Romanoff and Dr Adam McCarter

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Latest results

2024 Full Year Financial results

View Results Centre

2024 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: 14 November 2024

Read more

Back
to top